Autolus Therapeutics (AUTL) Projected to Post Earnings on Tuesday

Autolus Therapeutics (NASDAQ:AUTL) is anticipated to post its Q2 2025 quarterly earnings results before the market opens on Tuesday, August 12th. Analysts expect Autolus Therapeutics to post earnings of ($0.23) per share and revenue of $12.92 million for the quarter.

Autolus Therapeutics (NASDAQ:AUTL) last issued its earnings results on Thursday, May 8th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.02). The company had revenue of $8.98 million during the quarter, compared to the consensus estimate of $1.59 million. On average, analysts expect Autolus Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Autolus Therapeutics Price Performance

AUTL stock opened at $2.33 on Friday. Autolus Therapeutics has a 1-year low of $1.11 and a 1-year high of $5.00. The business has a 50 day simple moving average of $2.33 and a two-hundred day simple moving average of $1.90. The company has a market capitalization of $620.11 million, a price-to-earnings ratio of -2.65 and a beta of 1.90.

Hedge Funds Weigh In On Autolus Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Invesco Ltd. increased its stake in Autolus Therapeutics by 53.3% in the 1st quarter. Invesco Ltd. now owns 32,738 shares of the company’s stock worth $51,000 after acquiring an additional 11,381 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of Autolus Therapeutics by 90.5% in the second quarter. Geode Capital Management LLC now owns 164,314 shares of the company’s stock valued at $375,000 after purchasing an additional 78,058 shares in the last quarter. Finally, Jane Street Group LLC grew its holdings in shares of Autolus Therapeutics by 809.4% in the first quarter. Jane Street Group LLC now owns 102,493 shares of the company’s stock valued at $159,000 after purchasing an additional 91,222 shares in the last quarter. 72.83% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Separately, Needham & Company LLC restated a “buy” rating and set a $10.00 target price on shares of Autolus Therapeutics in a research report on Monday, July 21st. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $9.32.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.